Prolia® (denosumab) — Total revenues
Amgen Prolia® (denosumab) — Total revenues decreased by 7.5% to $1.05B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.5%, from $1.17B to $1.05B. Over 3 years (FY 2022 to FY 2025), Prolia® (denosumab) — Total revenues shows an upward trend with a 6.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption, successful commercial execution, or expanded clinical usage, while a decrease may signal increased competition, patent expiration, or market saturation.
Detailed definition
This metric represents the total gross sales generated by a specific therapeutic product line within the company's portf...
Peer comparison
Similar to product-specific revenue reporting in other large-cap pharmaceutical and biotechnology companies, which track the performance of key blockbuster drugs.
amgn_segment_prolia_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $814.00M | $803.00M | $852.00M | $922.00M | $862.00M | $992.00M | $927.00M | $1.03B | $986.00M | $1.11B | $999.00M | $1.17B | $1.05B | $1.17B | $1.10B | $1.12B | $1.14B | $1.05B |
| QoQ Change | — | -1.4% | +6.1% | +8.2% | -6.5% | +15.1% | -6.6% | +10.9% | -4.1% | +12.3% | -9.8% | +16.6% | -10.3% | +11.5% | -5.7% | +2.1% | +1.5% | -7.5% |
| YoY Change | — | — | — | +13.3% | +7.3% | — | +8.8% | +11.5% | +14.4% | +11.6% | +7.8% | +13.3% | +6.0% | +5.2% | +10.0% | -3.7% | +9.0% | -9.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's prolia® (denosumab) — total revenues?
- Amgen (AMGN) reported prolia® (denosumab) — total revenues of $1.05B in Q4 2025.
- How has Amgen's prolia® (denosumab) — total revenues changed year-over-year?
- Amgen's prolia® (denosumab) — total revenues decreased by 9.5% year-over-year, from $1.17B to $1.05B.
- What is the long-term trend for Amgen's prolia® (denosumab) — total revenues?
- Over 3 years (2022 to 2025), Amgen's prolia® (denosumab) — total revenues has grown at a 6.8% compound annual growth rate (CAGR), from $3.63B to $4.41B.
- What does prolia® (denosumab) — total revenues mean?
- The total amount of money earned from sales of a specific drug product.